HPM Web Site

  • HPM Web Site

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader




Disclaimer

  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2011 Hyman, Phelps & McNamara, P.C.

Awards & Honors










« D.C. District Court Grants FDA’s Motion to Dismiss/Summary Judgment in CYDECTIN PTE Case; Rules that FDA Rightly Decided that the PTE Review Phase Began Upon Submission of the CYDECTIN Administrative NADA | Main | Scientific Publication Calls for a Second Look at Setting a DRI for EPA and DHA »

March 23, 2009

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef01156e456f34970c

Listed below are links to weblogs that reference New York District Court Rebukes FDA Over PLAN B OTC Switch Approval Decision; Vacates FDA Citizen Petition Decision and Remands to FDA:

» Another route to 'arbitrary and capricious' from Administrative Law Prof Blog
From the FDA Law Blog of Hyman, Phelps & McNamara, P.C., "New York District Court Rebukes FDA Over PLAN B OTC Switch Approval Decision; Vacates FDA Citizen Petition Decision and Remands to FDA". In a scathing 52-page opinion issued [March... [Read More]

Comments

The comments to this entry are closed.